|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The loss of the (V599E)BRAF genotype during progression from primary to metastatic melanoma in patients with (V599E)BRaf specific T-cell responses suggests an active immune selection of nonmutated melanoma clones by the tumor-bearing host.
|
15289355 |
2004 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Treatment of metastatic melanoma with PLX4032 in patients with tumors that carry the V600E BRAF mutation resulted in complete or partial tumor regression in the majority of patients.
|
20818844 |
2010 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In August 2011 vemurafenib (Zelboraf; Daiichi Sankyo/Roche), an inhibitor of BRAF kinase, was approved by the US Food and Drug Administration (FDA) for the treatment of patients with unresectable or metastatic melanoma with the BRAF(V600E) mutation.
|
22037033 |
2011 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We conducted a phase 3 randomized clinical trial comparing vemurafenib with dacarbazine in 675 patients with previously untreated, metastatic melanoma with the BRAF V600E mutation.
|
21639808 |
2011 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We describe 3 patients with BRAF V600E mutation metastatic melanoma in whom treatment with vemurafenib resulted in prompt extracranial disease response but progression of metastatic disease in the brain.
|
23036672 |
2012 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Trametinib, as compared with chemotherapy, improved rates of progression-free and overall survival among patients who had metastatic melanoma with a BRAF V600E or V600K mutation.
|
22663011 |
2012 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Here, we describe a patient with metastatic melanoma (T1N2cM1a) with a BRAF V600E mutation.
|
22293660 |
2012 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma.
|
22535154 |
2012 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial.
|
23051966 |
2012 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We studied the efficacy of dabrafenib in patients with BRAF(V600E)-mutated metastatic melanoma.
|
22735384 |
2012 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Recent breakthroughs in the treatment of metastatic melanoma have arisen as a result of these significant new insights into the molecular biology of the disease, particularly the development of inhibitors of activating BRAF(V600E) mutations.
|
22723080 |
2012 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
B-RAF inhibitors (BRAFi) have been shown to improve rates of overall and progression-free survival in patients with stage IV metastatic melanoma positive for the BRAF V600E mutation.
|
22726224 |
2012 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Intra- and inter-tumor heterogeneity of BRAF(V600E))mutations in primary and metastatic melanoma.
|
22235286 |
2012 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The development of RAF inhibitors targeted against BRAF V600E mutant melanoma cells has revolutionized the treatment of MM.
|
23174497 |
2012 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Vemurafenib is an oral agent licensed for patients with BRAF V600E mutation-positive inoperable and metastatic melanoma.
|
23094782 |
2012 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRIM-1, -2 and -3 trials: improved survival with vemurafenib in metastatic melanoma patients with a BRAF(V600E) mutation.
|
22646765 |
2012 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Vemurafenib is an inhibitor of BRAF and is used to treat patients with metastatic melanoma who carry a V600E BRAF mutation.
|
23581649 |
2013 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
This article summarises the milestones in the development of dabrafenib leading to this first approval as a single agent treatment for unresectable or metastatic melanoma in patients with the BRAF V600E mutation.
|
23881668 |
2013 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Oral vemurafenib (Zelboraf(®)) is a first-in-class, small molecule BRAF(V600E) inhibitor indicated for the treatment of unresectable or metastatic melanoma in BRAF(V600) mutation-positive patients (EU) or BRAF(V600E) mutation-positive patients (USA).
|
23329082 |
2013 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The BRAF mutant, BRAF(V600E), is expressed in nearly half of melanomas, and oral BRAF inhibitors induce substantial tumor regression in patients with BRAF(V600E) metastatic melanoma.
|
23454771 |
2013 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Detection of the BRAF V600E mutation is required for use of the BRAF inhibitor, vemurafenib, in patients with metastatic melanoma.
|
23994118 |
2013 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
This study investigated the sensitivity and specificity of immunohistochemical (IHC) analysis using an anti-BRAF antibody to detect the presence of the BRAF V600E mutation in patients with metastatic melanoma.
|
23026937 |
2013 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Vemurafenib is a new-targeted therapy approved for the treatment of patients with V600E BRAF-mutant metastatic melanoma.
|
23528218 |
2013 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions.
|
23211290 |
2013 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma.
|
23403819 |
2013 |